For example, the evaluation of genetic variants of DBP-metabolizing enzymes in an epidemiological study on bladder cancer and THM exposure has shown that polymorphisms in key metabolizing enzymes modified DBP-associated bladder cancer risk (Cantor et al. 2010). The gene discussed is DBP; the disease is urinary bladder cancer.